(P1) Opus Genetics secured up to $160 million in a strategic financing deal with Oberland Capital, aiming to accelerate three new gene therapies for inherited retinal diseases into clinical trials over the next year.
(P2) "This strategic financing empowers us to accelerate our mission of bringing sight-saving gene therapies to patients with inherited retinal diseases," said Ben Yerxa, CEO of Opus Genetics.
(P3) The agreement includes up to $155 million in non-dilutive funding, with an immediate $35 million payment, and a concurrent $5 million equity investment by Oberland Capital. This extends Opus's cash runway from its current $100 million into 2029.
(P4) The financing provides Opus with the capital to complete pivotal studies for its lead candidates, OPGx-LCA5 and OPGx-BEST1, and potentially file for regulatory approval, a critical step for a clinical-stage biotech firm.
The capital injection allows Opus to significantly broaden its clinical efforts. The company confirmed that three additional programs from its early-stage pipeline will now advance into clinical testing over the next 12 months. This expansion is a significant step for the company, which is focused on developing treatments for rare inherited retinal diseases (IRDs), a group of genetic disorders that can cause severe vision loss and blindness.
The extended cash runway to 2029 de-risks the company's path to potential commercialization. It provides sufficient capital to move its lead programs, OPGx-LCA5 and OPGx-BEST1, through pivotal trials and potential regulatory submissions. For OPGx-BEST1, the company remains on track to report three-month topline data from the full first cohort of its Phase 1/2 trial by the middle of 2026.
The field of gene therapy for retinal diseases is competitive, with companies like Adverum Biotechnologies also developing treatments. However, Opus's focus on a broad portfolio of IRDs and its now-strengthened financial position could provide a competitive advantage. The non-dilutive nature of the majority of the funding is also a key benefit, as it minimizes shareholder dilution while providing a substantial runway. The potential to receive priority review vouchers upon approval of its therapies could also expedite the path to market for future treatments.
This article is for informational purposes only and does not constitute investment advice.
